ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 066

Baseline Kidney Biopsy in Lupus Patients Without Renal Manifestations. Underappreciated or Overrated?

Sai Sudha Mannemuddhu1, Lawrence Shoemaker 2, Shahab Bozorgmehri 3, Roberto Borgia 4, Nirupama Gupta 4, Larry Patterson 3, Kiran Upadhyay 3, Rupam Ruchi 3, Melissa Elder 4, Akaluck Thatayatikom 4, William Clapp 3, Xu Zeng 3 and Renee Modica 5, 1University of Florida, Gainesville, FL., Gainesville, 2University of Florida, Gainesville, Florida, 3University of Florida- College of Medicine, Gainesville, 4University of Florida, Gainesville, 5University of Florida, Gainseville, Orlando

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: baseline kidney biopsy, pediatrics, proliferative lupus nephritis, retrospective study, silent lupus nephritis

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Poster Session 1

Session Type: ACR Abstract Session

Session Time: 6:00PM-7:00PM

Background/Purpose: Lupus nephritis (LN) is seen in 20–75% of patients with pediatric Systemic Lupus Erythematosus (SLE). LN may present with abnormal urinary findings and/or renal impairment (overt LN-oLN) or manifest histologically only upon renal biopsy (silent LN-sLN). There is a dilemma regarding the indication for kidney biopsy in patients suspected of having sLN and if biopsy results affect clinical management decisions. However, there is insufficient data regarding this topic in pediatric lupus.
Objective: To investigate if baseline kidney biopsy will aid with early diagnosis of proliferative lupus in silent lupus nephritis patients

Methods: Our retrospective review included patients followed at the University of Florida, Gainesville. Patients were located through ICD-9 and ICD -10 codes for SLE and biopsy after IRB approval.

Inclusion Criteria:

  1. Children ≥ 1yo and ≤18 years old with SLE who had undergone kidney biopsy and has diagnosis of Lupus Nephritis.
  2. Patients diagnosed with SLE based on the American College of Rheumatology (ACR) 1997 criteria and/or Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria.

Exclusion Criteria:

  1. Pregnant patients
  2. Patients with diagnosis of SLE, but did not undergo renal biopsy or had no nephritis on biopsy.
  3. Patients diagnosed with SLE after 18 years of age.

Continuous variables were compared using Student’s t-test and categorical variables were compared using Fisher’s test.

Results:

  • oLN was more prevalent which was expected among the newly diagnosed lupus patients who had biopsies. Most of the patients with oLN were African Americans. (Fig 1)
  • In our pediatric cohort, 31% were found to have sLN and 27% (6/22) of them had proliferative LN, which was more prevalent in African American females with low C3. (Fig 2,3, and 4)
  • It is interesting to note that 100% of proliferative sLN were anti-dsDNA (+) with a median activity index of 5.5 vs 0 chronicity.
  • Arthritis and anemia were present in all patients with proliferative sLN. (Fig 3 and 4)

Conclusion:

  • Our study emphasizes the importance of performing a baseline kidney biopsy.
  • Renal biopsy might be considered in patients with very low C3, before the development of renal manifestations like hypertension, and decreased eGFR.
  • This approach might aid in early diagnosis and treatment. However, it is important to note that about 64% have Class I or II nephritis, which can give a false reassurance.
  • However, more studies are needed to understand if early diagnosis and treatment would modify long-term renal outcomes.

Figure 1: demographics and distribution of silent and overt lupus nephritis

Figure 2: Comparison of clinical features, lab and biopsy finds of Silent and overt lupus nephritis

Figure 3: Comparison of clinical features, lab and biopsy finds of Silent and overt proliferative lupus nephritis


Disclosure: S. Mannemuddhu, None; L. Shoemaker, None; S. Bozorgmehri, None; R. Borgia, None; N. Gupta, None; L. Patterson, None; K. Upadhyay, None; R. Ruchi, None; M. Elder, None; A. Thatayatikom, None; W. Clapp, None; X. Zeng, None; R. Modica, None.

To cite this abstract in AMA style:

Mannemuddhu S, Shoemaker L, Bozorgmehri S, Borgia R, Gupta N, Patterson L, Upadhyay K, Ruchi R, Elder M, Thatayatikom A, Clapp W, Zeng X, Modica R. Baseline Kidney Biopsy in Lupus Patients Without Renal Manifestations. Underappreciated or Overrated? [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/baseline-kidney-biopsy-in-lupus-patients-without-renal-manifestations-underappreciated-or-overrated/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-kidney-biopsy-in-lupus-patients-without-renal-manifestations-underappreciated-or-overrated/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology